Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Eradication

Objectives Tegoprazan, a novel potassium-competitive acid blocker with rapid and effective antisecretory activity, was approved for the treatment of Helicobacter pylori infections in Korea in March 2020. However, real-world data regarding tegoprazan-based therapies are scarce. We compared the effica...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Seokin Kang, Nam-Hoon Kim, Seokhyeon Jeong, Jong Wook Kim, Jung Rock Moon, Yoon Suk Lee, Jun Hyuk Son
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Korean College of Helicobacter and Upper Gastrointestinal Research 2024-06-01
Schriftenreihe:	The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Schlagworte:	potassium-competitive acid blockers proton pump inhibitors tegoprazan
Online-Zugang:	http://helicojournal.org/upload/pdf/kjhugr-2024-0012.pdf
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!